Equibles does not estimate personal net worth.
Get an email with a short summary when 4D Molecular Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FDMT alertsChris Simms has spoken on 2 investor events across 1 company, most recently for 4D Molecular Therapeutics, Inc. on May 19, 2026. 4D Molecular Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at 4D Molecular Therapeutics, Inc. includes David Kirn (CEO and Board Member), David Kirn, M.D. (CEO), Ashoo Gupta (CFO) and 7 others.
“And Christian, feel free to add an additional color. So I think there's a couple of things. First of all, I think we're setting out to reset a treatment paradigm and do something that hasn't been done before.”
“So, you know, you take a little bit of a step back and you're familiar with the category. It's a large space valued at roughly 17 billion dollars globally today with existing bolus anti-VEGF therapies.”
Transcript header (unverified)
Biotechnology · Healthcare
